Cargando…

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study

There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the time, especially in elderly patients. Thus, alterna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montaudié, Henri, Viotti, Julien, Combemale, Patrick, Dutriaux, Caroline, Dupin, Nicolas, Robert, Caroline, Mortier, Laurent, Kaphan, Régis, Duval-Modeste, Anne-Bénédicte, Dalle, Stéphane, De Quatrebarbes, Julie, Stefan, Andrea, Brunet-Possenti, Florence, Kogay, Maria, Picard-Gauci, Alexandra, Poissonnet, Gilles, Peyrade, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996917/ https://www.ncbi.nlm.nih.gov/pubmed/32064041 http://dx.doi.org/10.18632/oncotarget.27434

Ejemplares similares

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma
por: Becquart, Ondine, et al.
Publicado: (2021)

New Targeted Therapies and Immunotherapies for Locally Advanced Periocular Malignant Tumours: Towards a New ‘Eye-Sparing’ Paradigm?
por: Martel, Arnaud, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
por: Kandel, Marguerite, et al.
Publicado: (2022)

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)
por: Russo, David, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
por: Long-Mira, Elodie, et al.
Publicado: (2022)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
por: Gérard, Alexandre, et al.
Publicado: (2021)

Comparative Performance of Four Staging Classifications to Select «High-Risk» Head and Neck Cutaneous Squamous Cell Carcinomas
por: Elaldi, Roxane, et al.
Publicado: (2023)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

COVID-19 : adhésion à la vaccination chez des patients immunodéprimés de dermatologie
por: Lafon, Audrey, et al.
Publicado: (2021)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé
por: Skowron, F., et al.
Publicado: (2022)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
por: Vermorken, J. B., et al.
Publicado: (2014)

Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma
por: Ilié, Marius, et al.
Publicado: (2021)

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity
por: Cheli, Yann, et al.
Publicado: (2021)

ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity
por: Cheli, Yann, et al.
Publicado: (2021)

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
por: Guigay, Joël, et al.
Publicado: (2021)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature
por: Vuillamy, Chloé, et al.
Publicado: (2023)

Selection for Translational Efficiency in Genes Associated with Alphaproteobacterial Gene Transfer Agents
por: Kogay, Roman, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Los alimentos
por: Dupin, Henri
Publicado: (1992)

Los alimentos
por: Dupin, Henri
Publicado: (1985)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Validation of the integration of HIV and AIDS related nursing competencies into the undergraduate nursing curriculum in South Africa
por: Modeste, Regis R. Marie, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: Histologic and serologic findings from a new immunoassay
por: Hébert, Vivien, et al.
Publicado: (2020)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!
por: Luherne, Camille, et al.
Publicado: (2019)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
por: Vermorken, J. B., et al.
Publicado: (2014)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study
por: Legoupil, S., et al.
Publicado: (2022)

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
por: Gomes, Izabela N. F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lvd5hodb57b7f1n7d71ov150ci